Table 4.
Pathologic outcomes among all patients undergoing RP
| Active surveillance (n = 698) | Immediate RP (n = 552)* | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Baseline PSA>10 (n = 82) | PSA rise >10 (n = 157) | PSA ≤10 (n = 459) | p value | RP with PSA >10 (n = 63) | RP with PSA <10 (n = 489) | p value | ||
| RP (% of all treated) | 15 (46.9) | 22 (36.1) | 66 (48.9) | |||||
| Gleason score at RP (% of all RP-treated) | ≤3+3 | 8 (53.3) | 4 (18.2) | 20 (30.3) | 0.007 | 22(34.9) | 300 (61.4) | <0.001 |
| 3+4 | 4 (26.7) | 9 (40.9) | 38 (57.6) | 33(52.4) | 172 (35.2) | |||
| 4+3 | 3 (20) | 4 (18.2) | 5 (7.6) | 7 (11.1) | 14 (2.9) | |||
| ≥8 | 0 | 5 (22.7) | 3 (4.5) | 1 (1.6) | 3 (0.6) | |||
| Pathologic stage | pT2 | 43 | 440 | <0.001 | ||||
| pT3A | 12 | 38 | ||||||
| pT3B | 4 | 5 | ||||||
| pT4 | 4 | 6 | ||||||
| Positive margins (positive/total), (%) | 4 /14 (28.6) | 10/23 (43.5) | 16/63 (25.4) | 0.26 | 9/63 (14.5) | 61/492 (12.4) | 0.43 | |
RP: radical prostatectomy; PSA: prostate-specific antigen.
*
In 7 patients, biopsy data was available, but no Gleason score was available.